These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 16489006

  • 1. Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer.
    Hiraga T, Myoui A, Choi ME, Yoshikawa H, Yoneda T.
    Cancer Res; 2006 Feb 15; 66(4):2067-73. PubMed ID: 16489006
    [Abstract] [Full Text] [Related]

  • 2. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
    Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R.
    J Bone Miner Res; 2001 Aug 15; 16(8):1486-95. PubMed ID: 11499871
    [Abstract] [Full Text] [Related]

  • 3. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
    Singh B, Berry JA, Vincent LE, Lucci A.
    J Surg Res; 2006 Jul 15; 134(1):44-51. PubMed ID: 16678856
    [Abstract] [Full Text] [Related]

  • 4. COX-2 induces IL-11 production in human breast cancer cells.
    Singh B, Berry JA, Shoher A, Lucci A.
    J Surg Res; 2006 Apr 15; 131(2):267-75. PubMed ID: 16457848
    [Abstract] [Full Text] [Related]

  • 5. Insulin like growth factor binding protein-7 reduces growth of human breast cancer cells and xenografted tumors.
    Amemiya Y, Yang W, Benatar T, Nofech-Mozes S, Yee A, Kahn H, Holloway C, Seth A.
    Breast Cancer Res Treat; 2011 Apr 15; 126(2):373-84. PubMed ID: 20464481
    [Abstract] [Full Text] [Related]

  • 6. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
    Chirgwin JM, Guise TA.
    Crit Rev Eukaryot Gene Expr; 2000 Apr 15; 10(2):159-78. PubMed ID: 11186331
    [Abstract] [Full Text] [Related]

  • 7. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T.
    Cancer Res; 2007 May 01; 67(9):4157-63. PubMed ID: 17483326
    [Abstract] [Full Text] [Related]

  • 8. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
    Deckers M, van Dinther M, Buijs J, Que I, Löwik C, van der Pluijm G, ten Dijke P.
    Cancer Res; 2006 Feb 15; 66(4):2202-9. PubMed ID: 16489022
    [Abstract] [Full Text] [Related]

  • 9. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R, Rentsch C, Ten Dijke P, Cleton-Jansen AM, Driouch K, Lidereau R, Bachelier R, Vukicevic S, Clézardin P, Papapoulos SE, Cecchini MG, Löwik CW, van der Pluijm G.
    Cancer Res; 2007 Sep 15; 67(18):8742-51. PubMed ID: 17875715
    [Abstract] [Full Text] [Related]

  • 10. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M, Stapleton PP, Freeman TA, Gaughan JP, Matsuda T, Daly JM.
    J Am Coll Surg; 2004 Sep 15; 199(3):428-35. PubMed ID: 15325613
    [Abstract] [Full Text] [Related]

  • 11. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T.
    Cancer Res; 1995 Aug 15; 55(16):3551-7. PubMed ID: 7627963
    [Abstract] [Full Text] [Related]

  • 12. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T.
    Cancer Res; 1996 Sep 01; 56(17):4063-70. PubMed ID: 8752180
    [Abstract] [Full Text] [Related]

  • 13. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
    Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L.
    Cancer Res; 1999 Oct 01; 59(19):5041-6. PubMed ID: 10519421
    [Abstract] [Full Text] [Related]

  • 14. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
    Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, Siegel PM.
    Oncogene; 2009 Feb 19; 28(7):1005-15. PubMed ID: 19079339
    [Abstract] [Full Text] [Related]

  • 15. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.
    Oncogene; 2002 Jan 03; 21(1):108-18. PubMed ID: 11791181
    [Abstract] [Full Text] [Related]

  • 16. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT, Quinn JM, Sims NA, Vieusseux J, Waldeck K, Docherty SE, Myers D, Nakamura A, Waltham MC, Gillespie MT, Thompson EW.
    Cancer Res; 2005 Jun 01; 65(11):4929-38. PubMed ID: 15930315
    [Abstract] [Full Text] [Related]

  • 17. Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells.
    Sierra A, Price JE, García-Ramirez M, Méndez O, López L, Fabra A.
    Lab Invest; 1997 Oct 01; 77(4):357-68. PubMed ID: 9354770
    [Abstract] [Full Text] [Related]

  • 18. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
    Kominsky SL, Doucet M, Brady K, Weber KL.
    J Bone Miner Res; 2007 Jan 01; 22(1):37-44. PubMed ID: 17032147
    [Abstract] [Full Text] [Related]

  • 19. Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells.
    Hui AY, Dannenberg AJ, Sung JJ, Subbaramaiah K, Du B, Olinga P, Friedman SL.
    J Hepatol; 2004 Aug 01; 41(2):251-8. PubMed ID: 15288474
    [Abstract] [Full Text] [Related]

  • 20. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
    Zhao Y, Bachelier R, Treilleux I, Pujuguet P, Peyruchaud O, Baron R, Clément-Lacroix P, Clézardin P.
    Cancer Res; 2007 Jun 15; 67(12):5821-30. PubMed ID: 17575150
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.